id: sig-20260710-fezolinetant-mechanism
site_id: fezolinetant
site_hint: "fezolinetant — intervention"
attribute: mechanism
value: "Fezolinetant is a neurokinin 3 (NK3) receptor antagonist; the statement notes it as a first-in-class FDA-approved medication (recommended for vasomotor symptoms at Level I evidence)."
source_url: https://pubmed.ncbi.nlm.nih.gov/37252752/
source_title: "The Menopause Society — 2023 Nonhormone Therapy Position Statement (Menopause, 2023; PMID 37252752)"
publisher: The Menopause Society (Menopause journal)
source_date: "2023"
observed_date: "2026-07-10"
collected_by: gn_info_scout/1.0.0
confidence: high